The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Clovis Oncology, Inc. (Nasdaq: CLVS) (“Clovis” or the “Company”) securities during the period between October 31, 2013 and November 13, 2015 inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 19, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Clovis securities purchased on or after October 31, 2013 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at firstname.lastname@example.org or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company securities during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the New Drug Application (“NDA”) submitted by Clovis to the FDA for rociletinib, that Clovis’s Breakthrough Therapy designation submission, and that interim data presented by the Company publicly and at medical meetings included immature data sets based on both unconfirmed response rates and confirmed response rates and that as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected such that Clovis’ NDA was likely to be delayed and/or rejected by the FDA.
According to the complaint, following the Company’s November 16, 2015 press release revealing the foregoing and that the FDA requested additional clinical data for rociletinib, the value of Clovis shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153